Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules - Concepedia

Concepedia

Publication | Closed Access

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules

45

Citations

12

References

2010

Year

Ranjana H. Advani, Herbert I. Hurwitz, Michael S. Gordon, Scot Ebbinghaus, David S. Mendelson, Heather A. Wakelee, Ute Hoch, Jeffrey A. Silverman, N. Havrilla, Craig Berman,

Clinical Cancer Research

Abstract

Voreloxin showed an acceptable safety profile with clinical activity in patients with relapsed/refractory solid tumors. The MTD was schedule-dependent. Voreloxin is currently in clinical studies of ovarian cancer and acute myeloid leukemia.

References

	Year	Citations

Page 1